Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 16/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 16/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 16/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 16/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 16/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 14/20 | 1.00 |
| ▸ | GABRA6 | Q16445 | 9/20 | 1.00 |
| ▸ | GABRP | O00591 | 8/20 | 1.00 |
| ▸ | GABRD | O14764 | 8/20 | 1.00 |
| ▸ | GABRB1 | P18505 | 8/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 8/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 8/20 | 1.00 |
| ▸ | GABRE | P78334 | 8/20 | 1.00 |
| ▸ | GABRG1 | Q8N1C3 | 8/20 | 1.00 |
| ▸ | GABRG3 | Q99928 | 8/20 | 1.00 |
| ▸ | GABRQ | Q9UN88 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10374144 | 0.91 | GABRA1 (0.84) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9426137 | 0.89 | GABRA1 (0.81) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9425937 | 0.88 | GABRA1 (0.78) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9082460 | 0.87 | GABRA1 (0.77) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL10687277 | 0.87 | GABRA1 (0.77) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL10374361 | 0.86 | GABRA1 (0.76) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9369357 | 0.86 | GABRA1 (0.76) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL8908666 | 0.85 | GABRA1 (0.74) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL10389357 | 0.85 | GABRA1 (0.74) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL10707821 | 0.84 | GABRA1 (0.79) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230405018-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | BEXSON BIOMEDICAL, INC. | 2023-12-21 | — | — | US | claimed |
| US-20070043032-A1 | Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist | MAINVILLE, PIERRE (CA) | 2007-02-22 | — | — | US | claimed |
| EP-0128415-B1 | BETA-CARBOLIN-3-CARBOXYLIC ACID DERIVATIVES AND METHODS OF PREPARING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-08-31 | — | — | EP | claimed |
| US-4748179-A | β-carbolin-3-carboxylic acid derivatives and their use as benzodiazepine antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-05-31 | — | — | US | claimed |
| EP-0128415-A2 | Beta-carbolin-3-carboxylic acid derivatives and methods of preparing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-12-19 | — | — | EP | claimed |
| US-20230405018-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | BEXSON BIOMEDICAL, INC. | 2023-12-21 | — | — | US | disclosed |
| EP-4247386-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | Bexson Biomedical, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2022109052-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | BEXSON BIOMEDICAL, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20200085790-A1 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2020-03-19 | — | — | US | disclosed |
| US-20170231958-A1 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS | PHARNEXT S.A. (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | RESILIO COMPANY LIMITED (JP) | 2017-05-11 | — | — | US | disclosed |
| US-9636316-B2 | Baclofen and acamprosate based therapy of neurological disorders | PHARNEXT (FR) | 2017-05-02 | — | — | US | disclosed |
| US-6746678-B1 | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments | SECANT PHARMA, LLC | 2004-06-08 | — | — | US | disclosed |
| US-5668117-A | NERVOUS SYSTEM DISORDERS USING AROMATIC ACID COMPOUNDS | SECANT PHARMA, LLC | 1997-09-16 | — | — | US | disclosed |
| EP-0520987-A1 | METHOD OF SUPPRESSING APPETITE BY ADMINISTRATION OF TETRAHYDRO-$g(b)-CARBOLINE DERIVATIVES | NEUREX CORPORATION (US) | 1993-01-07 | — | — | EP | disclosed |
| US-4978669-A | ALTERING MACRONUTRIENT PREFERENCE | NEUREX CORPORATION (US) | 1990-12-18 | — | — | US | disclosed |
| WO-1990014827-A1 | METHOD OF SUPPRESSING APPETITE BY ADMINISTRATION OF TETRAHYDRO-β-CARBOLINE DERIVATIVES | NEUREX CORPORATION (US) | 1990-12-13 | — | — | WO | disclosed |
| EP-0128415-B1 | BETA-CARBOLIN-3-CARBOXYLIC ACID DERIVATIVES AND METHODS OF PREPARING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-08-31 | — | — | EP | disclosed |
| US-4748179-A | β-carbolin-3-carboxylic acid derivatives and their use as benzodiazepine antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-05-31 | — | — | US | disclosed |
| EP-0128415-A2 | Beta-carbolin-3-carboxylic acid derivatives and methods of preparing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230405018-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | GABBR1, GABBR2, GABRB2 | GABRA1 8/4885GABRG2 14/4885GABRB3 9/4885 |
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | GAP43, NGF, BDNF | GABRA1 3903/4885GABRG2 1687/4885GABRB3 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.